Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ODC1 | P11926 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43474 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL203118 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL2639323 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL202447 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL12775011 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL19107453 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL14745208 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL19107454 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL454356 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL13079441 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993710-B2 | Composite solid state electrolyte and lithium ion battery containing the same | WILDCAT DISCOVERY TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | claimed |
| CN-117178401-A | Composite solid electrolyte and lithium ion battery containing the same | 野猫技术开发公司 | 2023-12-05 | — | — | CN | claimed |
| WO-2022240599-A2 | COMPOSITE SOLID STATE ELECTROLYTE AND LITHIUM ION BATTERY CONTAINING THE SAME | WILDCAT DISCOVERY TECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| EP-4702004-A1 | NONIONIC SURFACTANTS | Detect, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20240360076-A1 | NONIONIC SURFACTANTS | DETECT INC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024150158-A1 | IL-7 POLYPEPTIDES, IMMUNOCYTOKINES COMPRISING SAME, AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| US-11993710-B2 | Composite solid state electrolyte and lithium ion battery containing the same | WILDCAT DISCOVERY TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-117178401-A | Composite solid electrolyte and lithium ion battery containing the same | 野猫技术开发公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230303649-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-09-28 | — | — | US | disclosed |
| CN-116712386-A | High-absorptivity hydrogel grafted with digestive enzyme inhibitor, and preparation method and application thereof | 厦门君德医药科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-2023281483-A1 | MODIFIED TNF-ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023281481-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023281480-A1 | CONJUGATES OF CHECKPOINT INHIBITORS WITH IL-2, AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023281485-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023281484-A1 | SYNTHETIC IL-7 AND IL-7 IMMUNOCYTOKINES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022240599-A2 | COMPOSITE SOLID STATE ELECTROLYTE AND LITHIUM ION BATTERY CONTAINING THE SAME | WILDCAT DISCOVERY TECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022038417-A2 | MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2022-02-24 | — | — | WO | disclosed |
| US-20220056002-A1 | PHOTOCLEAVABLE LINKER FOR CATCHING AND/OR RELEASING OF CIRCULATING TUMOR CELLS OR EXTRA CELLULAR VESICLES | THE UNIVERSITY OF KANSAS (US) | 2022-02-24 | — | — | US | disclosed |
| US-20210252157-A1 | MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056002-A1 | PHOTOCLEAVABLE LINKER FOR CATCHING AND/OR RELEASING OF CIRCULATING TUMOR CELLS OR EXTRA CELLULAR VESICLES | EXOSC10, ADAM10, HCCS | MEN1 830/4885KMT2A 1296/4885ODC1 4065/4885 |
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | PDCD1, CD274, PDCD1LG2 | MEN1 1239/4885KMT2A 2529/4885ODC1 1377/4885 |
| US-20240360076-A1 | NONIONIC SURFACTANTS | POLL, POLRMT, POLI | MEN1 4035/4885KMT2A 3615/4885ODC1 3387/4885 |
| US-20230303649-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | IL2, IL2RA, ICOS | MEN1 4197/4885KMT2A 1964/4885ODC1 4667/4885 |
| US-20210252157-A1 | MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF | IL2, IL2RA, IL6ST | MEN1 4459/4885KMT2A 1747/4885ODC1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.